Development of a synthetic Vi polysaccharide vaccine for typhoid fever
Ni Y, Springer MJ, Guo J, et al. Development of a synthetic Vi polysaccharide vaccine for typhoid fever. Vaccine. 2017;35:7121–7126. Read Here >
An ambient temperature-stable anti toxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E
Li M, Lee D, Obi CR, Freeberg JK, Farr-Jones S, Tomic MT. An ambient temperature-stable anti toxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E. PLoSONE 2018.13(5):e0197011. Read Here >
Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder.
Ball JP, Springer MJ, Ni Y, Finger-Baker I, Martinez J, Hahn J, et al. Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder. PLoSONE. 2017;12(5):e0177310 Read Here >
Zika Virus: Medical Countermeasure Development Challenges.
Malone RW, Homan J, Callahan MV, Glasspool-Malone J, Damodaran L, Schneider ADB, et al. Zika virus: medical countermeasure development challenges. 2016 PLoS Negl Trop Dis. 10(3): e0004530. Read Here >
Preclinical Dose Ranging Studies of a Novel Dry Powder Norovirus Vaccine Formulation
Springer MJ, Ni Y, Finger-Baker I, et al. Preclinical dose ranging studies of a novel dry powder norovirus vaccine formulation. Vaccine. 2016;34(12):1452–1458. Read Here>
Ology Bioservices and RAFA Laboratories Announce FDA Approval of the Atropine Autoinjector
Ology Bioservices and RAFA Laboratories Announce FDA Approval of the Atropine Autoinjector as a Medical Countermeasure for Chemical Nerve Agents ALACHUA, Fla. & JERUSALEM--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), and Rafa Laboratories, Ltd. (Rafa), a leading Israeli pharmaceutical company, today announced that on July 9, 2018, [...]
Ology Bioservices to Develop Vaccine Candidate Against Malaria for The Global Health Initiative Fund
Ology Bioservices will develop the large-scale, process development and manufacturing plan and supply the AnAPN1 vaccine candidate for use in ongoing pre-clinical studies and to prepare for subsequent clinical testing.
Ology Bioservices Strengthens Board of Directors
Ology Bioservices Strengthens Board of Directors with Appointment of Industry Veterans James M. Robinson and Gerard Cunningham Former Merck & Co. Executives Bring Deep Expertise in Development and Manufacturing of Vaccines and Biologicals ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics-focused contract development and manufacturing organization (CDMO) serving both government and commercial clients, [...]
Nanotherapeutics Announces Name Change to Ology Bioservices
Nanotherapeutics Announces Name Change to Ology Bioservices, Reflecting the Company’s Ongoing Transformation into One of the Top Contract Development and Manufacturing Organizations of Vaccines and Biologics ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc. today announced that the Company has changed its name to Ology Bioservices, Inc., effective immediately. The name change is part of a [...]
Peter H. Khoury, Ph.D., MBA Appointed President and Chief Executive Officer of Nanotherapeutics
ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc., a biologics focused contract development and manufacturing organization (CDMO), today announced that Peter H. Khoury, Ph.D., MBA, formerly Senior Vice President and Chief Commercial Officer, has been appointed President and Chief Executive Officer of the Company.